Last updated: 16 February 2024 at 5:25pm EST

Farrell Simon Net Worth




The estimated Net Worth of Farrell Simon is at least $151 Tisíc dollars as of 20 June 2023. Farrell Simon owns over 6,250 units of Trevi Therapeutics stock worth over $150,645 and over the last 2 years Farrell sold TRVI stock worth over $0.

Farrell Simon TRVI stock SEC Form 4 insiders trading

Farrell has made over 2 trades of the Trevi Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Farrell exercised 6,250 units of TRVI stock worth $3,188 on 20 June 2023.

The largest trade Farrell's ever made was exercising 18,750 units of Trevi Therapeutics stock on 7 March 2023 worth over $9,563. On average, Farrell trades about 6,250 units every 26 days since 2023. As of 20 June 2023 Farrell still owns at least 45,650 units of Trevi Therapeutics stock.

You can see the complete history of Farrell Simon stock trades at the bottom of the page.



What's Farrell Simon's mailing address?

Farrell's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.

Insiders trading at Trevi Therapeutics

Over the last 5 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett a Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.



What does Trevi Therapeutics do?

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.



What does Trevi Therapeutics's logo look like?

Trevi Therapeutics, Inc. logo

Complete history of Farrell Simon stock trades at Trevi Therapeutics

Datum
#
Společnost
Osoba
Trans.
Transakce
Počet akcií Cena za akcii Celková cena Počet akcií po Zdroj
20 Jun 2023 Farrell Simon
Chief Commercial Officer
Využití opce 6,250 $0.51 $3,188
20 Jun 2023
45,650
7 Mar 2023 Farrell Simon
Chief Commercial Officer
Využití opce 18,750 $0.51 $9,563
7 Mar 2023
39,400


Trevi Therapeutics executives and stock owners

Trevi Therapeutics executives and other stock owners filed with the SEC include: